All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Sybrava 284mg Injection
Prescription Required
Salt Composition : Inclisiran
Manufacturer : NOVARTIS INDIA LTD
Origin of Medicine : Switzerland
1 Prefilled Syringe(s) Of 1.5ml
Introduction to Sybrava 284mg Injection
Sybrava 284 mg Injection is a medicine containing Inclisiran as an active ingredient which belongs to the class of medications called proprotein convertase subtilisin kexin type-9 [PCSK-9]. It is first in class and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol. It is used to lower the level of low density lipoprotein. It is prescribed as a complement to statin medication and diet in the management of patients with primary high cholesterol levels.
It is not recommended to use this medication if you are allergic to the active compound Sybrava 284 mg Injection or its components. It is not recommended to use during pregnancy and breastfeeding; it is advised to consult your physician regarding further queries. It is not recommended for children and adolescents under the age of 18. You should be taking a statin and following a diet to reduce your cholesterol before beginning this therapy. For the duration that you are receiving Sybrava 284 mg Injection, you should continue taking the statin and adhering to this cholesterol-lowering diet. Do not stop taking this medicine without consulting your doctor. Talk to your doctor if you have kidney disorders, breathing problems, liver disorders, heart problems, or intolerance to sugars before taking this medicine. Inform your physician or pharmacist of any additional medications you are taking, have recently taken, or may take, including over-the-counter medications and herbal remedies.
Uses of Sybrava 284mg Injection
- Combination to other statin therapy and diet for treating primary hyperlipidemia [heterozygous familial hypercholesterolemia]
Therapeutic Effects of Sybrava 284mg Injection
Sybrava 284 mg Injection is a small interfering RNA (siRNA) molecule that interferes with the production of PCSK9 protein in the liver. By inhibiting PCSK9 synthesis, Sybrava 284 mg Injection increases the number of LDL receptors on liver cells, promoting the clearance of LDL cholesterol from the blood. This mechanism ultimately leads to lower LDL cholesterol levels in the bloodstream, helping to reduce the risk of cardiovascular events such as heart attack and stroke.
Interaction of Sybrava 284mg Injection with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Sybrava 284 mg Injection and reduce effectiveness by causing undesirable side effects.
More Information about Sybrava 284mg Injection
- Sybrava 284 mg Injection should be stored at room temperature, between 20°C to 25°C (68°F to 77°F).
- Protected from light.
- Keep it in its original packaging until it is ready to be used.
- Keep out of the reach of children and pets.
- Should be disposed of properly.
How to consume Sybrava 284mg Injection
Sybrava 284 mg Injection will be administered to you by a healthcare professional in a hospital setting. It is usually administered as a subcutaneous injection into the abdomen, upper arm, or thigh. Your doctor will decide the dose, route of administration, and frequency based on your disease condition and other factors. The second dose is given after 3 months and the subsequent dose every 6 months.
Safety Advices for Sybrava 284mg Injection
Pregnancy
It is recommended to avoid this medication during pregnancy as Sybrava 284 mg Injection is unsafe during pregnancy as it can cause fetal harm. It is advised to inform your physician if you are pregnant or think you may be pregnant before starting the treatment.
Breast Feeding
It is unknown whether Sybrava 284mg Injection is excreted in human milk. It is advised to consult your doctor before taking Sybrava 284 mg Injection. Your doctor may prescribe this if the benefits of the drug outweighs the risks involved.
Lungs
It is unknown whether Sybrava 284 mg Injection Injection is safe for patients with lung problems. Consult your doctor if you have lung disease before starting the treatment.
Liver
Sybrava 284 mg Injection is primarily metabolized in the liver, so inform your healthcare provider if you have any liver problems or diseases.
Alcohol
It is unknown if consuming alcoholic beverages while taking Sybrava 284 mg Injection injection is safe. Please consult with your physician.
Driving
It is safe to travel, drive a car, or operate heavy machinery after receiving Sybrava 284mg Injection. The drug does not impair alertness or coordination.
Side Effects of Sybrava 284mg Injection
Like all medications, Sybrava 284 mg Injection can cause side effects, although not everyone who takes it will experience them.
Common:
- Injection site reactions like redness, rash and pain
- Arthralgia
- Bronchitis
- Fever
- Chills
- Headache
Word of Advice
It is advised to adopt heart-healthy lifestyle practices, such as eating a balanced diet low in saturated and trans fats, exercising frequently, keeping a healthy weight, and quitting smoking, in addition to taking Sybrava 284 mg Injection. It is advised not to stop your regular statin medications and follow proper diet since Sybrava 284 mg Injection is only effective along with these two therapies. It is not recommended to discontinue the drug without the advice of a healthcare professional even if your symptoms improve. Follow your doctor's advice and routinely check your cholesterol levels. This facilitates monitoring Sybrava 284 mg Injection's efficacy and enables prompt modification of your treatment regimen, if necessary. If a dose is missed for more than three months, a new dosing regimen needs to be initiated.
FAQs
Q 1. Can Sybrava 284 mg Injection be used during pregnancy or breastfeeding?
The safety of Sybrava 284 mg Injection during pregnancy and breastfeeding has not been established. It is important to consult with a healthcare provider before using Sybrava 284 mg Injection if you are pregnant, planning to become pregnant, or breastfeeding.
Q 2. How often do I need to have my cholesterol levels checked while taking Sybrava 284 mg Injection?
Your healthcare provider will determine how often you need to have your cholesterol levels checked based on your individual health status and treatment response. Regular monitoring of cholesterol levels is typically recommended during Sybrava 284 mg Injection therapy.
Q 3. Can I stop taking my other cholesterol-lowering medications if I start Sybrava 284 mg Injection?
It is important to follow your healthcare provider's instructions regarding the use of other cholesterol-lowering medications while taking Sybrava 284 mg Injection. Sybrava 284 mg Injection may be used in addition to other medications to achieve optimal cholesterol control.
Q 4. What should I do if I miss a dose of Sybrava 284 mg Injection?
If you miss a dose of Sybrava 284 mg Injection, contact your healthcare provider to reschedule the missed dose. Usually Sybrava 284 mg Injection is given at an interval of 3 months. It is important to maintain the prescribed dosing schedule to ensure the effectiveness of Sybrava 284 mg Injection therapy in lowering LDL cholesterol levels.
Q 5. What are the common side effects of Sybrava 284 mg Injection?
Common side effects of Sybrava 284 mg Injection may include injection site reactions (such as pain, redness, or swelling), flu-like symptoms (such as fever, chills, or body aches), and headache. These side effects are usually mild and temporary.
Fact Box of Sybrava 284mg Injection
Molecule name: Inclisiran
| Therapeutic class: Antihyperlipidemic drugs |
Pharmacological class: Proprotein convertase subtilisin kexin type-9 [PCSK-9] | Indications: Combination to other statin therapy and diet for treating primary hyperlipidemia [heterozygous familial hypercholesterolemia ] |
Dosage form: Injection
| Habit forming: No |
References
- Novartis Pharmaceuticals Corporation , US Food and Drug Administration, [ Revised on July 2023] [ Accessed on 05-03-2024 ], https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/214012s009lbl.pdf
- Novartis Pharmaceuticals UK Ltd. Electronic medicines compendium (emc), [ Revised on November 2022] [ Accessed on 05-03-2024], https://www.medicines.org.uk/emc/files/pil.12039.pdf
- Leqvio, Novartis Pharmaceuticals Ltd, https://www.leqvio.com/
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
